

Special Issue

Immunity to Influenza Viruses and Vaccines: 2nd Edition

Message from the Guest Editor

Influenza viruses are highly prevalent pathogens transmitted by air droplets or direct contact. Vaccination is the recommended strategy for the prevention and control of influenza. Both previous influenza infections and vaccinations shape individual immunity and impact vaccine response. Immunity to influenza comprises both innate and adaptive components. To promote the development of control and prevention of influenza, we are launching a Special Issue entitled “Immunity to Influenza Viruses and Vaccines: 2nd Edition”. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: antiviral and anti-influenza immunity, immunological responses to potential viral vaccine antigens, the delivery methods of viral vaccine antigens, studies on vaccine adjuvants related to viral vaccine development, investigations of viral vaccine strategies that aim to raise broadly neutralizing antibodies, and theoretical studies that suggest and rationalize novel types of viral vaccines or novel ways of stimulating protective antiviral immunity. We look forward to receiving your contributions.

Guest Editor

Dr. Rongbao Gao

Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Deadline for manuscript submissions

31 January 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/271324

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).